G1 THERAPEUTICS (NASDAQ:GTHX) Director Fredric N. Eshelman purchased 250,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was acquired at an average price of $19.73 per share, for a total transaction of $4,932,500.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of G1 THERAPEUTICS (NASDAQ GTHX) traded down $0.29 during trading on Wednesday, reaching $19.42. The company had a trading volume of 76,800 shares, compared to its average volume of 89,938. G1 THERAPEUTICS has a 1 year low of $12.04 and a 1 year high of $28.67.
ILLEGAL ACTIVITY WARNING: “Insider Buying: G1 THERAPEUTICS (GTHX) Director Buys 250,000 Shares of Stock” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/16/insider-buying-g1-therapeutics-gthx-director-buys-250000-shares-of-stock.html.
A number of institutional investors have recently made changes to their positions in the stock. RA Capital Management LLC bought a new stake in G1 THERAPEUTICS in the second quarter valued at about $46,813,000. FMR LLC bought a new stake in G1 THERAPEUTICS in the second quarter valued at about $34,093,000. Emerald Advisers Inc. PA grew its holdings in shares of G1 THERAPEUTICS by 2.5% during the third quarter. Emerald Advisers Inc. PA now owns 728,433 shares of the company’s stock valued at $18,131,000 after purchasing an additional 17,977 shares during the last quarter. Franklin Resources Inc. bought a new position in shares of G1 THERAPEUTICS during the second quarter valued at approximately $10,651,000. Finally, Hillhouse Capital Management Ltd. bought a new position in shares of G1 THERAPEUTICS during the second quarter valued at approximately $7,848,000. 35.28% of the stock is owned by hedge funds and other institutional investors.
About G1 THERAPEUTICS
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.